BACKGROUND: Current US FDA-approved biological therapies for treating smoking target central nervous system processes. Although these therapies have had some success, relapse within a year is still high. Clearly additional strategies are needed to aid individuals in maintaining abstinence. OBJECTIVE/ METHODS: We briefly discuss promising research using vaccines to combat smoking and then identify some potentially important directions for future research. RESULTS/ CONCLUSIONS: Immunization with a nicotine vaccine generates drug-specific antibodies that sequester some of the nicotine in the peripheral circulation preventing it from entering the brain, thus decreasing its addictive effects. Albeit promising, much more research is necessary to identify more efficacious vaccine designs and formulations, as well as optimal immunization regimens. A further understanding of the factors contributing to the substantial individual differences in immunogenicity to these vaccines and how to best use vaccines in combination with other treatment strategies will increase the success of intervention efforts.
BACKGROUND: Current US FDA-approved biological therapies for treating smoking target central nervous system processes. Although these therapies have had some success, relapse within a year is still high. Clearly additional strategies are needed to aid individuals in maintaining abstinence. OBJECTIVE/ METHODS: We briefly discuss promising research using vaccines to combat smoking and then identify some potentially important directions for future research. RESULTS/ CONCLUSIONS: Immunization with a nicotine vaccine generates drug-specific antibodies that sequester some of the nicotine in the peripheral circulation preventing it from entering the brain, thus decreasing its addictive effects. Albeit promising, much more research is necessary to identify more efficacious vaccine designs and formulations, as well as optimal immunization regimens. A further understanding of the factors contributing to the substantial individual differences in immunogenicity to these vaccines and how to best use vaccines in combination with other treatment strategies will increase the success of intervention efforts.
Authors: Patrik Maurer; Gary T Jennings; Jörg Willers; Franziska Rohner; Ylva Lindman; Kirsten Roubicek; Wolfgang A Renner; Philipp Müller; Martin F Bachmann Journal: Eur J Immunol Date: 2005-07 Impact factor: 5.532
Authors: Jennifer L Oliver; Ghazaleh Pashmi; Paul Barnett; Pascal Mettens; Ralph Biemans; Philippe Monteyne; Rémi Palmantier; Timothy Gallagher; Sharn Ramaya; Susan Wonnacott Journal: Vaccine Date: 2007-08-30 Impact factor: 3.641
Authors: Sam D Sanderson; Srinivasa R Cheruku; Maniyan P Padmanilayam; Jonathan L Vennerstrom; Geoffrey M Thiele; Matthew I Palmatier; Rick A Bevins Journal: Int Immunopharmacol Date: 2003-01 Impact factor: 4.932
Authors: Joseph R DiFranza; Judith A Savageau; Kenneth Fletcher; Judith K Ockene; Nancy A Rigotti; Ann D McNeill; Mardia Coleman; Constance Wood Journal: Addict Behav Date: 2004-02 Impact factor: 3.913
Authors: M Pravetoni; D E Keyler; M D Raleigh; A C Harris; M G Lesage; C K Mattson; S Pettersson; P R Pentel Journal: Biochem Pharmacol Date: 2011-02-17 Impact factor: 5.858
Authors: M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492